Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]:
SEC Accession No. 0000950170-25-038770
Filing Date
2025-03-13
Accepted
2025-03-13 16:20:29
Documents
116
Period of Report
2024-12-31

Document Format Files

Seq Description Document Type Size
1 10-K rgnx-20241231.htm   iXBRL 10-K 4609700
2 EX-4.2 rgnx-ex4_2.htm EX-4.2 68720
3 EX-19.1 rgnx-ex19_1.htm EX-19.1 98568
4 EX-21.1 rgnx-ex21_1.htm EX-21.1 4623
5 EX-23.1 rgnx-ex23_1.htm EX-23.1 4288
6 EX-31.1 rgnx-ex31_1.htm EX-31.1 12917
7 EX-31.2 rgnx-ex31_2.htm EX-31.2 12917
8 EX-32.1 rgnx-ex32_1.htm EX-32.1 12349
9 GRAPHIC img150455437_0.jpg GRAPHIC 1154606
10 GRAPHIC img150455437_1.jpg GRAPHIC 174029
11 GRAPHIC img150455437_2.jpg GRAPHIC 553347
  Complete submission text file 0000950170-25-038770.txt   22871093

Data Files

Seq Description Document Type Size
12 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rgnx-20241231.xsd EX-101.SCH 2124049
119 EXTRACTED XBRL INSTANCE DOCUMENT rgnx-20241231_htm.xml XML 3837791
Mailing Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850
Business Address 9804 MEDICAL CENTER DRIVE ROCKVILLE MD 20850 240-552-8181
REGENXBIO Inc. (Filer) CIK: 0001590877 (see all company filings)

EIN.: 471851754 | Fiscal Year End: 1231
Type: 10-K | Act: 34 | File No.: 001-37553 | Film No.: 25736077
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)